primary hepatocellular carcinoma
Conditions
Interventions
Flurbiprofen ester group:None
Sponsors
Shenzhen Traditional Chinese Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Patients with confirmed primary or metastatic hepatocellular carcinoma, with Child–Pugh class A–B liver function, undergoing TACE treatment. 2. Age 18–85 years, regardless of sex. 3. No history of allergy to opioid medications. 4. No preoperative hepatic pain or only mild pain that does not affect quality of life and does not require analgesic treatment. 5. American Society of Anesthesiologists (ASA) physical status classification I–II. 6. Underwent TACE treatment with complete records of analgesic use and postoperative NRS pain scores.
Exclusion criteria
Exclusion criteria: 1. Pre-TACE pain score >=7 on the pain rating scale. 2. History of substance abuse or use of opioid analgesics for any reason within 7 days prior to the procedure. 3. Coexisting malignancies other than liver cancer. 4. Severe hepatic or renal dysfunction, coagulation disorders, or severe cardiopulmonary impairment. 5. History of severe respiratory depression, asthma, or gastrointestinal paralysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety Outcomes;NRS pain score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total Rescue Analgesic Dose; | — |
Countries
China
Contacts
Public ContactHaihui Deng
Shenzhen Traditional Chinese Hospital
Outcome results
None listed